Evidence map›Paper›PMID 40465067›Full record

ReviewMolecular neurobiology2025

The Effect of Metformin on Astrocytes in Parkinson's Disease: Challenges and Opportunities.

Hayder M Al-Kuraishy, Ghassan M Sulaiman, Hebatallah M Saad, Hamdoon A Mohammed, Mosleh M Abomughaid, Ali I Al-Gareeb, Ali K Albuhadily

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hayder M Al-KuraishyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Ghassan M SulaimanDepartment of Biotechnology, College of Applied Sciences, University of Technology, Baghdad, Iraq. ghassan.m.sulaiman@uotechnology.edu.iq.
Hebatallah M SaadDepartment of Pathology, Faculty of Veterinary Medicine, Matrouh University, Marsa Matruh, Egypt.
Hamdoon A MohammedDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim, Saudi Arabia.
Mosleh M AbomughaidDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia.
Ali I Al-GareebJabir Ibn Hayyan Medical University, Al-Ameer Qu., PO.Box13 Kufa, Najaf, Iraq.
Ali K AlbuhadilyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease that represents the most common movement disorder in old-age subjects. The development of PD neuropathology is due to the progressive accumulation of alpha-synuclein (α-Syn) in the dopaminergic neurons of the substantia nigra pars compacta (SNpc). Moreover, astrocytes are intricate in the pathogenesis of PD that has neuroprotective effects against oxidative stress in PD by releasing antioxidant and anti-inflammatory mediators. The physiological properties of astrocytes are altered in PD due to the progressive accumulation of α-Syn, which induces mitochondrial dysfunction, oxidative stress, and inflammation. In addition, genetic mutations in PD also impact the antioxidant and anti-inflammatory properties of astrocytes. The functional role of astrocytes is extremely distorted in PD. Therefore, restoration of the anti-inflammatory and antioxidant effects of astrocytes could be an alternative therapeutic strategy in the management of PD. It has been shown that the anti-diabetic metformin improves the anti-inflammatory and antioxidant effects of astrocytes in different neurodegenerative diseases, including PD. Nevertheless, the mechanisms that relate to the effect of metformin on astrocytes in PD are not completely elucidated. Consequently, this review aims to discuss the astroprotective effect of metformin in PD with regard to the underlying mechanisms.

Indexed as

AstrocytesMetforminParkinson DiseaseAnimalsAntioxidantsHumansNeuroprotective AgentsOxidative StressAntioxidantsMetforminNeuroprotective AgentsAstroprotective effectMetforminParkinson’s diseasePathogenesis

Identifiers

PMID40465067

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.